Today
Biotech company Alterity Therapeutics seeking to raise $40m
MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.
- Sarah Thompson, Kanika Sood and Emma Rapaport
January
The scientist-turned-banker’s mission to fund cancer breakthrough
Alan Taylor has swapped his early years on the sports field and a stint as an investment banker for the boardroom, in his quest to get medical breakthroughs to patients.
- Michael Smith
Spray-on skin hopeful Avita Medical nosedives 19pc on revenue miss
The regenerative medicine company disappointed its shareholders with a revenue miss that has dragged down full-year results as hospitals slowed buying.
- Kanika Sood
December 2024
Millions in debt, but this CSL challenger is still tapping investors
Aegros has promised new management and a new board in the hopes of wooing investors. But its promising blood plasma technology looks further away than ever.
- Yolanda Redrup
Mesoblast shares rocket on FDA approval, but CEO says risks remain
FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow transplants is a breakthrough for the biotech.
- Michael Smith
Market darling LTR Pharma raises new equity
The shares were offered at 92¢ apiece, which represented a 21.6 per cent discount to the 10-day volume-weighted average price.
- Sarah Thompson, Kanika Sood and Emma Rapaport
This ASX biotech stock could be the next M&A target
Antares’ portfolio manager Andrew Hamilton says a key drug of Immutep has “enormous potential revenue”.
- Joanne Tran
Biotech NEXSEN set to launch pre-IPO round: 2025 IPO pencilled in
The biotech, which has been working towards commercial development of its IP since March 2022, is targeting ASX quotation in April next year.
- Sarah Thompson, Kanika Sood and Emma Rapaport
November 2024
- Exclusive
- Venture capital
Hostplus’ $125m VC bet signals super’s resurgent interest in start-ups
Higher financing costs have made it a difficult period for new tech firms. But the last month has seen a resurgence in interest from retirement funds.
- Paul Smith
The stock set to propel one of WA’s richest back onto the Rich List
Alan Tribe’s net worth has soared in line with ASX-listed PYC Therapeutics, which after more than 23 years in businesses is finally on the edge of success.
- Yolanda Redrup
CSL tumbles as investors fear RFK jnr’s vaccine plans
The White House appointment of the anti-vax conspiracy theorist is devastating ASX healthcare and biotech shares as he threatens to turn the FDA ‘on its head’.
- Updated
- Joshua Peach and Joanne Tran
Frozen Perth fund made a big bet on a German cannabis stock
Accounts for the $70-odd million vehicle show more than a third of its FUM is held in a single unlisted medicinal company.
- Sarah Thompson, Kanika Sood and Emma Rapaport
High-profile Perth fund manager freezes redemptions
Merchant’s other fund, the biotech fund, remains open, liquid and top-performing, delivering 24.73 per cent returns over the past six months.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Wilsons healthcare analyst jumps to Barrenjoey
Melissa Benson will work alongside Nick McGarrigle and Josh Kannourakis in the emerging companies team.
- Sarah Thompson, Kanika Sood and Emma Rapaport
October 2024
Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise
The company expects its implants to be commercially available in the US market in 2027.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Vitrafy Life Sciences fast-tracks IPO bookbuild
Vitrafy looks like it would raise $35 million for its ASX debut. Three existing investors – Regal, Thorney and Ryder Capital – are cornerstoning the book.
- Sarah Thompson, Kanika Sood and Emma Rapaport
CSL pulls studies, trials on three therapies in late-stage setback
The biotech giant has not ruled out expanding its pipeline of treatments through acquisitions after a number of projects were put on hold.
- Michael Smith
Ballarat’s Vitrafy Life Sciences preps IPO bookbuild for $117.5m float
IPO hopeful Vitrafy is led by Wesfarmers non-executive director and former Virtus Health boss Kate Munnings.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Meet the powerful sovereign wealth fund circling TPG’s $4b Novotech
It’s Singapore slings all round for dealmakers at Bain Capital and EQT with management meetings set for the last week of October.
- Sarah Thompson, Kanika Sood and Emma Rapaport
West African explorer Turaco Gold in $35m placement
A term sheet sent to potential investors said the miner would use the proceeds to fund drilling, metallurgical test work and infrastructure at its Afema project in Cote d’Ivoire.
- Sarah Thompson, Kanika Sood and Emma Rapaport